Bibliographical noteFunding Information:
Funding/Support: Study design, conduct, and data collection were supported by the Abramson Cancer Center Breast Cancer Pilot and Breakthrough Bike Challenge, the National Cancer Institute (P30 CA016520), Basser Center for BRCA, METAvivor, Burroughs Wellcome Fund, and Susan G. Komen (CCR16376362). Support for design and conduct of the study was provided by the National Institutes of Health (K01DA040023, K08CA215312, RO1-CA196528), Susan G. Komen (CCR16376362, SAC130060), the Burroughs Wellcome Fund, and the American Roentgen Ray Society. Support for collection, management, analysis, and interpretation of the data was provided by the National Cancer Institute (P30 CA016520), METAvivor, and the Abramson Cancer Center Breakthrough Bike Challenge.
Funding/Support: This work was supported in part by grant P30 CA77598 from the National Institutes of Health Masonic Cancer Center.
Conflict of Interest Disclosures: Dr Farwell reports receiving grants from Merck and Bristol-Myers Squibb. Dr Mach reports receiving personal fees from Five Eleven Pharma; having a patent pending for a 211At-targeted radiotherapy based on poly–(adenosine diphosphate–ribose) polymerase 1; being a cofounder of and having a US patent license for Trevarx, a company with a license to the patent for the positron emission tomographic imaging agent used in this study; being a cofounder of Accuronix Therapeutics and Vellum Biosciences; and serving on the scientific advisory board of Cognition Therapeutics. Dr Mankoff reports that his spouse is the chief executive officer of Trevarx, a company with a license to the patent for the positron emission tomographic imaging agent used in this study. Dr McDonald reports receiving grants from the National Cancer Institute, Susan G. Komen, METAvivor, the American Roentgen Ray Society, the US Department of Defense, and the National Institutes of Health. No other disclosures are reported.